FINWIRES · TerminalLIVE
FINWIRES

Keyence, Fanuc Shares Climb, Chugai Declines as Japan Stocks Mixed After Earnings

By

Japanese stocks that reported recent earnings traded mixed on Monday, with gains led by companies posting solid profit growth and shareholder returns, while one major drugmaker declined despite higher quarterly earnings.

Keyence (TYO:6861) shares jumped 16% after reporting full-year results, with net income attributable to owners of parent rising 12% to 445.19 billion yen as revenue increased 10% to 1.169 trillion yen. The company raised its annual dividend to 550 yen per share from 350 yen.

Fanuc (TYO:6954) shares also gained 16% after posting annual results, with net income attributable to owners of parent climbing 13% to 166.54 billion yen, while revenue rose 8% to 857.83 billion yen.

The company expects full-year net income attributable to owners of the parent of 184.9 billion yen and revenue of 909.6 billion yen for the financial year ending March 31, 2027. It also raised its annual dividend to 107.09 yen per share from 94.39 yen.

Meanwhile, Chugai Pharmaceutical (TYO:4519) fell 16% despite reporting stronger first-quarter earnings. Net income attributable to shareholders rose 19% to 115.42 billion yen as revenue increased 12% to 321.75 billion yen. The company expects full-year revenue of 1.345 trillion yen and core net income of 485 billion yen, with an annual dividend forecast of 132 yen per share.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA